Warner Chilcott is in market with $4.4 billion in loan financing and debt financing following the company's acquisition by drug manufacturer Actavis.
The big pharma company is looking to raise $2 billion in new term loan financing.
Warner Chilcott is also looking to amend and extend $2.4 billion of existing senior secured credit facilities at the Actavis level.
Proceeds from the two new term loans and $425 million in cash will repay $2.45 billion of existing Warner Chilcott bank debt financing.
The amended loans, meanwhile, will replace a $1.8 billion term loan Actavis entered in June 2012 and a $750 million revolver from September 2011.
Bank of America Merrill Lynch and JP Morgan are joint bookrunners for the debt financing round.
BAML, JP Morgan HSBC, Bank of Tokyo-Mitsubishi and Mizuho are joint lead arrangers for the debt financing round.
The new facilities consist of a $1 billion, three-year term loan and a $1 billion, five-year term loan.
The amended facilities consist of a $1.65 billion, four year term loan and a $750 million revolver.
Report: Partnering Deals and Alliances with Actavis (formerly Watson Pharmaceuticals)
Report: Partnering Deals and Alliances with Warner Chilcott
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity